FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208932116> ?p ?o ?g. }

• W3208932116 endingPage "2578" @default.
• W3208932116 startingPage "2569" @default.
• W3208932116 abstract "The comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT) trial showed that following induction, treatment with the sublingual agonist (buprenorphine-naloxone, BUP-NX) or injected antagonist (extended release naltrexone, XR-NTX) produced similar reductions in opioid relapse in injection users with opioid use disorder (OUD). Because XR-NTX reduces drinking in alcohol use disorder (AUD), we conducted a secondary analysis of the X:BOT sample of patients successfully inducted onto treatment to determine whether XR-NTX (n = 204) was superior to BUP-NX (n = 270) in reducing drinking or heavy drinking in patients with OUD.Standard drink units consumed were measured using the Timeline Follow-back method. Mixed-models regression was used to examine the monthly frequency of any drinking and heavy drinking over 6 months of treatment. We used a proportional hazard survival analysis to examine the time to first drink.Both treatment groups reduced drinking from baseline to posttreatment (small to medium effect), but no differences between groups were detected. However, only 29% (n = 136) of the sample had AUD and 19% (n = 26/136) of those were abstinent before treatment. Analysis of a subsample enriched for possible drinking included 136 individuals with an AUD diagnosis plus 43 who did not have AUD, but reported at least one day of heavy drinking prior to the study. However, this subsample reported only 32% of days of any drinking with a median of only 13% of days designated as heavy. Within this subsample, at baseline, the BUP-NX group reported more mean drinks per drinking day than the XR-NTX group (p = 0.03); however, there were no other significant group differences on drinking observed before, during, or at the end of treatment.There was an overall reduction in drinking during treatment of OUD using both agonist and antagonist medications, so that the hypothesis that XR-NTX would be superior to BUP-NX was not supported. The study is limited by low levels of comorbid AUD or heavy drinking observed in X:BOT trial participants seeking treatment for OUD." @default.
• W3208932116 created "2021-11-08" @default.
• W3208932116 creator A5016262149 @default.
• W3208932116 creator A5053541541 @default.
• W3208932116 creator A5071920736 @default.
• W3208932116 creator A5073707428 @default.
• W3208932116 creator A5077667294 @default.
• W3208932116 creator A5079969867 @default.
• W3208932116 creator A5086344811 @default.
• W3208932116 creator A5087899369 @default.
• W3208932116 date "2021-11-23" @default.
• W3208932116 modified "2023-10-16" @default.
• W3208932116 title "Is extended release naltrexone superior to buprenorphine‐naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial" @default.
• W3208932116 cites W1623733931 @default.
• W3208932116 cites W1770934634 @default.
• W3208932116 cites W1974741209 @default.
• W3208932116 cites W1990391721 @default.
• W3208932116 cites W2002105418 @default.
• W3208932116 cites W2010906830 @default.
• W3208932116 cites W2032105912 @default.
• W3208932116 cites W2036259797 @default.
• W3208932116 cites W2048849975 @default.
• W3208932116 cites W2055782614 @default.
• W3208932116 cites W2066840940 @default.
• W3208932116 cites W2076078537 @default.
• W3208932116 cites W2076293542 @default.
• W3208932116 cites W2077358351 @default.
• W3208932116 cites W2083060011 @default.
• W3208932116 cites W2093559862 @default.
• W3208932116 cites W2101372918 @default.
• W3208932116 cites W2103050138 @default.
• W3208932116 cites W2104538950 @default.
• W3208932116 cites W2112963881 @default.
• W3208932116 cites W2116745456 @default.
• W3208932116 cites W2119681201 @default.
• W3208932116 cites W2120690735 @default.
• W3208932116 cites W2132974770 @default.
• W3208932116 cites W2136222996 @default.
• W3208932116 cites W2138742021 @default.
• W3208932116 cites W2140407904 @default.
• W3208932116 cites W2143190301 @default.
• W3208932116 cites W2158010305 @default.
• W3208932116 cites W2164678034 @default.
• W3208932116 cites W2168472107 @default.
• W3208932116 cites W2327966153 @default.
• W3208932116 cites W2413464033 @default.
• W3208932116 cites W2512537769 @default.
• W3208932116 cites W2517268165 @default.
• W3208932116 cites W2517652980 @default.
• W3208932116 cites W2560157258 @default.
• W3208932116 cites W2565728627 @default.
• W3208932116 cites W2567850197 @default.
• W3208932116 cites W2626583042 @default.
• W3208932116 cites W2747986097 @default.
• W3208932116 cites W2768214444 @default.
• W3208932116 cites W2805243591 @default.
• W3208932116 cites W2902655755 @default.
• W3208932116 cites W2945782078 @default.
• W3208932116 cites W2995330948 @default.
• W3208932116 cites W3008003623 @default.
• W3208932116 doi "https://doi.org/10.1111/acer.14729" @default.
• W3208932116 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34698397" @default.
• W3208932116 hasPublicationYear "2021" @default.
• W3208932116 type Work @default.
• W3208932116 sameAs 3208932116 @default.
• W3208932116 citedByCount "2" @default.
• W3208932116 countsByYear W32089321162022 @default.
• W3208932116 countsByYear W32089321162023 @default.
• W3208932116 crossrefType "journal-article" @default.
• W3208932116 hasAuthorship W3208932116A5016262149 @default.
• W3208932116 hasAuthorship W3208932116A5053541541 @default.
• W3208932116 hasAuthorship W3208932116A5071920736 @default.
• W3208932116 hasAuthorship W3208932116A5073707428 @default.
• W3208932116 hasAuthorship W3208932116A5077667294 @default.
• W3208932116 hasAuthorship W3208932116A5079969867 @default.
• W3208932116 hasAuthorship W3208932116A5086344811 @default.
• W3208932116 hasAuthorship W3208932116A5087899369 @default.
• W3208932116 hasBestOaLocation W32089321162 @default.
• W3208932116 hasConcept C118552586 @default.
• W3208932116 hasConcept C126322002 @default.
• W3208932116 hasConcept C170493617 @default.
• W3208932116 hasConcept C185592680 @default.
• W3208932116 hasConcept C207103383 @default.
• W3208932116 hasConcept C2775962371 @default.
• W3208932116 hasConcept C2777972943 @default.
• W3208932116 hasConcept C2778750930 @default.
• W3208932116 hasConcept C2778949969 @default.
• W3208932116 hasConcept C2779418921 @default.
• W3208932116 hasConcept C2779442783 @default.
• W3208932116 hasConcept C2780687700 @default.
• W3208932116 hasConcept C2781063702 @default.
• W3208932116 hasConcept C2781066024 @default.
• W3208932116 hasConcept C42219234 @default.
• W3208932116 hasConcept C44249647 @default.
• W3208932116 hasConcept C55493867 @default.
• W3208932116 hasConcept C71924100 @default.
• W3208932116 hasConceptScore W3208932116C118552586 @default.
• W3208932116 hasConceptScore W3208932116C126322002 @default.

• next